Search results for "associated fatty liver disease"

showing 3 items of 3 documents

Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease.

2021

BACKGROUND & AIMS: Fatty liver disease (FLD) is a growing epidemic that is expected to be the leading cause of end-stage liver disease within the next decade. Both environmental and genetic factors contribute to the susceptibility of FLD. Several genetic variants contributing to FLD have been identified in exome-wide association studies. However, there is still a missing hereditability indicating that other genetic variants are yet to be discovered. METHODS: To find genes involved in FLD, we first examined the association of missense and nonsense variants with alanine amino transferase at an exome-wide level in 425,671 participants from the UK Biobank. We then validated genetic variants wit…

0301 basic medicineGenome-wide association studyLiver disease0302 clinical medicineENRICHMENT ANALYSISNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseExomeCONFERS SUSCEPTIBILITYGeneticsINSULIN-RESISTANCEmedicine.diagnostic_testFatty liverGastroenterologyAlanine Transaminase1-Acylglycerol-3-Phosphate O-Acyltransferase3. Good healthGENOMEEuropePhenotypeLiver biopsy030211 gastroenterology & hepatologyNonalcoholic Fatty Liver DiseaseMAFLDSingle-nucleotide polymorphismBiologyTransaminaseRisk Assessment03 medical and health sciencesApolipoproteins ENAFLDmedicineGenetic predispositionHumansGenetic Predisposition to DiseaseHEPATIC STEATOSISGenetic associationMAFLD Phenotype Reproducibility of Results Risk Assessment Risk Factors Transcriptome Genetic Variation Metabolic Associated Fatty Liver Disease Nonalcoholic Fatty Liver Disease Transaminase 1-Acylglycerol-3-Phosphate O-Acyltransferase Alanine Transaminase Apolipoproteins E Biomarkers Europe Exome Gene Expression Profiling Genetic Predisposition to Disease Genome-Wide Association Study Humans Non-alcoholic Fatty Liver DiseaseHepatologyMUTATIONSGene Expression ProfilingGenetic VariationReproducibility of Resultsmedicine.diseaseX-RECEPTORGENE030104 developmental biology3121 General medicine internal medicine and other clinical medicineMetabolic Associated Fatty Liver DiseaseRNA-SEQ DATATranscriptomePATHOGENICITYBiomarkersGenome-Wide Association StudyGastroenterology
researchProduct

Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus.

2021

This article also appears in: Health, Medical, and Life Sciences Virtual Issue for Advanced Science.

FGF21General Chemical EngineeringGeneral Physics and AstronomyMedicine (miscellaneous)CODON USAGE BIAS02 engineering and technology01 natural sciencesGLUCOSEACTIVATIONPF-05231023ComputingMilieux_COMPUTERSANDEDUCATIONGeneral Materials SciencegeneticsCells CulturedINSULIN-RESISTANCEFull PaperFatty liverQGeneral Engineeringfibroblast growth factor 21 genetics metabolic metabolic associated fatty liver disease Cells Cultured Enzyme-Linked Immunosorbent Assay Fatty Liver Fibroblast Growth Factors Humans Inflammation LiverFull Papers021001 nanoscience & nanotechnologyPhenotype3. Good healthLiverOBESITY221 Nano-technology0210 nano-technologyReprogrammingEXPRESSIONmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAScienceEnzyme-Linked Immunosorbent Assayfibroblast growth factor 21Biology010402 general chemistryBiochemistry Genetics and Molecular Biology (miscellaneous)metabolic associated fatty liver diseaseInsulin resistancemetabolicInternal medicinemedicineHumansSecretionFGF21 RESISTANCEAlleleInflammationmedicine.disease0104 chemical sciencesFatty LiverFibroblast Growth FactorsEndocrinologyRNA SECONDARY STRUCTURETRANSLATIONHormoneAdvanced science (Weinheim, Baden-Wurttemberg, Germany)
researchProduct

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis : A longitudinal study of 1893 biopsy-proven no…

2021

[Background and Aim] Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We assessed the NASH distribution and its components across the fibrosis stages and their impact on the prognosis and their relationship with the concept of metabolic-associated fatty liver disease (MAFLD).

Liver Cirrhosismedicine.medical_specialtyCirrhosisSteatosisBiopsyGastroenterologydigestive systemBallooning03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFatty liver diseaseInternal medicineBiopsyNonalcoholic fatty liver diseasemedicineassociated fatty liver diseaseMetabolic-associated fatty liver diseaseHumansmetabolic&#8208Longitudinal StudiesFirst episodeInflammationHepatologymedicine.diagnostic_testballooning fatty liver disease inflammation metabolic-associated fatty liver disease natural coursesteatohepatitis steatosisbusiness.industryFatty liverNatural coursesteatohepatitismedicine.diseasedigestive system diseasesLiver030220 oncology & carcinogenesis030211 gastroenterology & hepatologySteatosisSteatohepatitisbusiness
researchProduct